Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care
| Autor: | Peter M. Haddad, O. S. Niaz |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Mental Health Services medicine.medical_specialty Time Factors Adolescent medicine.drug_class Drug misuse Cost-Benefit Analysis Atypical antipsychotic Recurrence Medicine Humans In patient Psychiatry Aged Risperidone business.industry Dopamine antagonist Health Care Costs Middle Aged medicine.disease United Kingdom Hospitalization Psychiatry and Mental health Long acting Tolerability Schizophrenia Delayed-Action Preparations Injections Intravenous Female business medicine.drug Antipsychotic Agents |
| Zdroj: | Acta psychiatrica Scandinavica. 116(1) |
| ISSN: | 0001-690X |
| Popis: | Objective: To report the use of risperidone long-acting injection (RLAI) in a UK psychiatric service. Method: Retrospective case note review of all patients prescribed RLAI over a 35-month period. In the mirror-image analysis patients initiated on RLAI as in-patients had the index admission attributed to previous treatment. Results: Patients prescribed RLAI had significantly higher baseline rates of drug misuse, alcohol misuse, unemployment and forensic markers than control patients prescribed oral antipsychotics. Most patients started RLAI because of poor compliance with oral antipsychotics. Inefficacy accounted for more discontinuations than intolerability. Fifty-eight percent (39/67) of patients were continuing RLAI 12 months after initiation. Mirror-image analysis (n = 74) showed that RLAI was associated with a reduction in the number of admissions (65 vs. 33, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|